Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Amortization of Deferred Charges: 2013-2023

Historic Amortization of Deferred Charges for Adma Biologics (ADMA) over the last 2 years, with Dec 2023 value amounting to $877,000.

  • Adma Biologics' Amortization of Deferred Charges fell 9.97% to $877,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.8 million, marking a year-over-year increase of 27.08%. This contributed to the annual value of $3.8 million for FY2023, which is 27.95% up from last year.
  • Per Adma Biologics' latest filing, its Amortization of Deferred Charges stood at $877,000 for Q4 2023, which was down 11.68% from $993,000 recorded in Q3 2023.
  • In the past 5 years, Adma Biologics' Amortization of Deferred Charges ranged from a high of $1.0 million in Q2 2022 and a low of $877,000 during Q4 2023.
  • Its 2-year average for Amortization of Deferred Charges is $976,286, with a median of $980,000 in 2023.
  • The largest annual percentage gain for Adma Biologics' Amortization of Deferred Charges in the last 5 years was 1.51% (2023), contrasted with its biggest fall of 9.97% (2023).
  • Adma Biologics' Amortization of Deferred Charges (Quarterly) stood at $974,068 in 2022, then declined by 9.97% to $877,000 in 2023.
  • Its Amortization of Deferred Charges was $877,000 in Q4 2023, compared to $993,000 in Q3 2023 and $986,000 in Q2 2023.